A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523819-11-00

Enrollment

Registered

2026-07-27

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Cell Lung Cancer

Brief summary

Objective Response (OR) as Measured by Overall Response Rate (ORR) Based on Blinded Independent Central Review (BICR), Overall Survival (OS)

Detailed description

Progression-free survival (PFS) based on BICR assessment per RECIST v1.1., Duration of response (DoR) based on BICR assessment per RECIST v1.1., Change from baseline at Week 12 in physical functioning as measured by the physicalfunctioning domain of the EORTC QLQ-C30., Change from baseline at Week 12 in Global Health Status (GHS)/Quality of life (QoL) as measured by the EORTC QLQ-C30 GHS/QoL scale

Interventions

DRUGTOPOTECAN

DRUGABBV-706

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective Response (OR) as Measured by Overall Response Rate (ORR) Based on Blinded Independent Central Review (BICR), Overall Survival (OS)	—

Secondary

Measure	Time frame
Progression-free survival (PFS) based on BICR assessment per RECIST v1.1., Duration of response (DoR) based on BICR assessment per RECIST v1.1., Change from baseline at Week 12 in physical functioning as measured by the physicalfunctioning domain of the EORTC QLQ-C30., Change from baseline at Week 12 in Global Health Status (GHS)/Quality of life (QoL) as measured by the EORTC QLQ-C30 GHS/QoL scale	—

Measure

Time frame

—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 29, 2026